KRAS and carcinoma: The Ras/MAPK (Ras/mitogen activated protein kinases) pathway and its continuous activation, due to mutations presented in codon 12 of the KRAS gene, plays an important role in treatment resistance in patients with various carcinomas, including CRC [42].